A carregar...

Imipenem/Cilastatin/Relebactam Alone and in Combination against Pseudomonas aeruginosa in the In Vitro Pharmacodynamic Model

Combination therapy may enhance imipenem/cilastatin/relebactam’s (I/R) activity against Pseudomonas aeruginosa and suppress resistance development. Human-simulated unbound plasma concentrations of I/R at 1.25 g every 6 h (h), colistin at 360 mg daily, and amikacin at 25 mg/kg daily were reproduced a...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Antimicrob Agents Chemother
Main Authors: Chen, Iris H., Nicolau, David P., Kuti, Joseph L.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Microbiology 2020
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7674065/
https://ncbi.nlm.nih.gov/pubmed/33139283
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.01764-20
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!